The effect of nintedanib on lung functions and survival in
idiopathic pulmonary fibrosis: real-life analysis of the Czech
EMPIRE registry

J 2023

The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry

ŠTEFÁNIKOVÁ, Marianna; Martina DOUBKOVÁ; Petra OVESNÁ; Martina STERCLOVA; Ladislav LACINA et al.

Základní údaje

Originální název

The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry

Autoři

Vydání

BMC Pulmonary Medicine, London, BMC, 2023, 1471-2466

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.600

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/23:00131022

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Idiopathic pulmonary fibrosis; Nintedanib; Lung function decline; Overall survival

Štítky

14110215, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 2. 2025 09:59, Mgr. Tereza Miškechová

Anotace

V originále

IntroductionThe antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic treatment outcome in real-world cohorts of Czech EMPIRE registry.Patients/methodsData of 611 Czech IPF subjects, 430 (70%) treated with nintedanib (NIN group), 181 (30%) with no-antifibrotic treatment (NAF group) were analysed. The influence of nintedanib on overall survival (OS), pulmonary function parameters as forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO), as well as GAP score (gender, age, physiology) and and CPI (composite physiological index) were investigated.ResultsDuring 2 year follow-up we observed that nintedanib treated patients had longer OS, compared to those treated with no-antifibrotic drugs (p < 0.00001). Nintedanib reduces risk of mortality over no-antifibrotic treatment by 55% (p < 0.001). We have observed no significant difference in the rate of FVC and DLCO decline between the NIN and NAF group. Changes within 24 months from baseline in CPI were not significant between the groups (NAF and NIN).ConclusionOur real-practice study showed the benefit of nintedanib treatment on survival. There were no significant differences between NIN and NAF groups in changes from baseline in FVC %, DLCO % predicted and CPI.

Citovat

ŠTEFÁNIKOVÁ, Marianna; Martina DOUBKOVÁ; Petra OVESNÁ; Martina STERCLOVA; Ladislav LACINA; Monika ZURKOVA; Martina PLACKOVA; Vladimir BARTOS; Ivana JANICKOVA; Radka BITTENGLOVA; Jan ANTON; Lubica SÝKOROVÁ; Vladimira LOSTAKOVA; Pavlina MUSILOVA; Hana SULDOVA; Radka MOKOSOVA; Jurij DIDYK; Lenka SISAKOVA; Pavlina LISA; Jaroslav LNENICKA; Hana DARICKOVA; Daniel DOLEZEL; Jana PSIKALOVA; Richard TYL; Renata KRALOVA a Martina KOZIAR VASAKOVA. The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry. BMC Pulmonary Medicine. London: BMC, 2023, roč. 23, č. 1, s. 1-9. ISSN 1471-2466. Dostupné z: https://doi.org/10.1186/s12890-023-02450-3.

@article{2292980,
   author = {Štefániková, Marianna and Doubková, Martina and Ovesná, Petra and Sterclova, Martina and Lacina, Ladislav and Zurkova, Monika and Plackova, Martina and Bartos, Vladimir and Janickova, Ivana and Bittenglova, Radka and Anton, Jan and Sýkorová, Lubica and Lostakova, Vladimira and Musilova, Pavlina and Suldova, Hana and Mokosova, Radka and Didyk, Jurij and Sisakova, Lenka and Lisa, Pavlina and Lnenicka, Jaroslav and Darickova, Hana and Dolezel, Daniel and Psikalova, Jana and Tyl, Richard and Kralova, Renata and Koziar Vasakova, Martina},
   article_location = {London},
   article_number = {1},
   doi = {https://doi.org/10.1186/s12890-023-02450-3},
   keywords = {Idiopathic pulmonary fibrosis; Nintedanib; Lung function decline; Overall survival},
   language = {eng},
   issn = {1471-2466},
   journal = {BMC Pulmonary Medicine},
   title = {The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry},
   url = {https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-023-02450-3},
   volume = {23},
   year = {2023}
}

TY  - JOUR
ID  - 2292980
AU  - Štefániková, Marianna - Doubková, Martina - Ovesná, Petra - Sterclova, Martina - Lacina, Ladislav - Zurkova, Monika - Plackova, Martina - Bartos, Vladimir - Janickova, Ivana - Bittenglova, Radka - Anton, Jan - Sýkorová, Lubica - Lostakova, Vladimira - Musilova, Pavlina - Suldova, Hana - Mokosova, Radka - Didyk, Jurij - Sisakova, Lenka - Lisa, Pavlina - Lnenicka, Jaroslav - Darickova, Hana - Dolezel, Daniel - Psikalova, Jana - Tyl, Richard - Kralova, Renata - Koziar Vasakova, Martina
PY  - 2023
TI  - The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry
JF  - BMC Pulmonary Medicine
VL  - 23
IS  - 1
SP  - 1-9
EP  - 1-9
PB  - BMC
SN  - 14712466
KW  - Idiopathic pulmonary fibrosis
KW  - Nintedanib
KW  - Lung function decline
KW  - Overall survival
UR  - https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-023-02450-3
N2  - IntroductionThe antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic treatment outcome in real-world cohorts of Czech EMPIRE registry.Patients/methodsData of 611 Czech IPF subjects, 430 (70%) treated with nintedanib (NIN group), 181 (30%) with no-antifibrotic treatment (NAF group) were analysed. The influence of nintedanib on overall survival (OS), pulmonary function parameters as forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO), as well as GAP score (gender, age, physiology) and and CPI (composite physiological index) were investigated.ResultsDuring 2 year follow-up we observed that nintedanib treated patients had longer OS, compared to those treated with no-antifibrotic drugs (p < 0.00001). Nintedanib reduces risk of mortality over no-antifibrotic treatment by 55% (p < 0.001). We have observed no significant difference in the rate of FVC and DLCO decline between the NIN and NAF group. Changes within 24 months from baseline in CPI were not significant between the groups (NAF and NIN).ConclusionOur real-practice study showed the benefit of nintedanib treatment on survival. There were no significant differences between NIN and NAF groups in changes from baseline in FVC %, DLCO % predicted and CPI.
ER  -

ŠTEFÁNIKOVÁ, Marianna; Martina DOUBKOVÁ; Petra OVESNÁ; Martina STERCLOVA; Ladislav LACINA; Monika ZURKOVA; Martina PLACKOVA; Vladimir BARTOS; Ivana JANICKOVA; Radka BITTENGLOVA; Jan ANTON; Lubica SÝKOROVÁ; Vladimira LOSTAKOVA; Pavlina MUSILOVA; Hana SULDOVA; Radka MOKOSOVA; Jurij DIDYK; Lenka SISAKOVA; Pavlina LISA; Jaroslav LNENICKA; Hana DARICKOVA; Daniel DOLEZEL; Jana PSIKALOVA; Richard TYL; Renata KRALOVA a Martina KOZIAR VASAKOVA. The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry. \textit{BMC Pulmonary Medicine}. London: BMC, 2023, roč.~23, č.~1, s.~1-9. ISSN~1471-2466. Dostupné z: https://doi.org/10.1186/s12890-023-02450-3.

Přehled o publikaci